
    
      This is a pilot trial to determine if milrinone infusion in neonates â‰¥ 36 weeks'
      postmenstrual age (PMA) at birth with CDH would lead to an increase in PaO2 with a
      corresponding decrease in OI by itself or in conjunction with other pulmonary vasodilators
      such as iNO at 24 h post-infusion.
    
  